TheraVida has developed a proprietary and patent-protected product, where a positive-acting agent (“agonist”) with a delayed-onset, immediate-release profile is added to an inhibiting agent (“antagonist”) to create a combination therapeutic with a goal of reducing or eliminating problematic side effects for patients.

This customized dosage and timing of release of the “agonist” is critical to the success of the TheraVida technology.

TheraVida has tested its novel combination drug technology in multiple human trials showing maintenance of therapeutic effect with improved patient tolerability. This improved tolerability is expected to result in greater patient satisfaction allowing improvements in long-term compliance and clinical outcomes.